Many of the diagnoses that unlock GLP-1 Bridge eligibility are biomarker-driven
Clinical trials demonstrate its effectiveness, with Semaglutide (2.4 mg weekly) showing approximately 14.9% mean weight loss over 68 weeks in individuals with overweight or obesity without diabetes
During the Super Bowl, telehealth platform Hims & Hers released a controversial ad calling out drugmakers that provide weight loss drugs priced for profits, not patients. It then proceeded to highlight its compounded GLP-1 offerings, calling them affordable, doctor-trusted and formulated in the USA. Shortly after, Novo Nordisk responded to the ad with its own Check before you inject campaign, highlighting the argument that patients should be wary of compounded GLP-1s given that they arent FDA-approved products
It includes a fortified blend of organic prebiotics that may slow digestion, fortify the GI tract, and boost metabolism
When NNMT methylates nicotinamide, it creates a compound called 1-methylnicotinamide
As a result, the FDA has recommended against the use of compounded GLP-1 medications, despite making it legal to sell them